Elsevier

Journal of Clinical Virology

Volume 64, March 2015, Pages 128-136
Journal of Clinical Virology

Hantaviruses—Globally emerging pathogens

https://doi.org/10.1016/j.jcv.2014.08.033Get rights and content

Highlights

  • This review characterizes hantaviruses as emerging zoonotic viruses.

  • Hantaviruses are present on various continents including tropical and subtropical regions.

  • Progress in hantavirus epidemiology and diagnostics during the previous decade is summarized.

  • We discuss the influence of ecological factors on the worldwide virus distribution.

  • The paper gives an outlook on research perspectives for the next years.

Abstract

Hantaviruses are emerging zoonotic viruses which cause human disease in Africa, America, Asia, and Europe. This review summarizes the progress in hantavirus epidemiology and diagnostics during the previous decade. Moreover, we discuss the influence of ecological factors on the worldwide virus distribution and give an outlook on research perspectives for the next years.

Introduction

Hantavirus disease is a zoonosis. The causative viruses, collectively belonging to the genus Hantavirus of the Bunyaviridae family, are harbored by small mammals as reservoir hosts and transmitted to men. In humans, they cause febrile disease, usually named “Hemorrhagic Fever with Renal Syndrome” (HFRS) for disease in Asia and Europe and “Hantavirus Cardiopulmonary Syndrome” (HCPS) in the Americas with case fatality rates of up to 35–50% [67], [48], [45], [18]. The pathogenesis of hantavirus disease is characterized by changes in blood coagulation, vasodilatation and disturbances in the barrier function of the capillaries, resulting in extravasion of blood and inflammatory processes in the affected organs. Since pathogenesis is highly similar and clinical appearance is overlapping between both syndromes, comprehensive terms as “hantavirus disease” or “hantavirus fever” have been suggested to denote the disease [12], [92].

Virus transmission to humans occurs via inhalation of aerosolized rodent urine, saliva, and feces, rarely by rodent bites. In the environment, virus particles remain infectious for several weeks – depending on factors as humidity, temperature, and association with protective proteins [22]. An overview about the risk factors of hantavirus infections was very recently compiled by Watson et al. [98]; the most prominent factors are involvement in outdoor activities, such as rural- and forest-related activities, peridomestic rodent presence, exposure to potentially infected dust, and outdoor military training. Humans are usually considered to be dead-end hosts who do not transmit the virus further. However, indubitable human-to-human transmission of Andes hantavirus was reported in Argentina and Chile [99], [63], [9], [53], [14].

According to the presence of infected animal hosts and their contacts to humans, occurrence of hantavirus disease can be observed in different climatic zones including subtropics and tropics. Hantaviruses are considered to belong to the group of emerging viruses; this has mainly to do with the frequent identification of novel hantaviruses and their role as human pathogens. There are different trends in the development of case numbers; whereas in China – the country with most HFRS cases per year worldwide – the number of patients seems to decrease because of the vaccination approaches in this country [23], the number of cases in Europe and particularly Germany shows a clear increase over the last years [70], [46].

Here, we will refer to the progress in hantavirus epidemiology and diagnostics during the previous decade (see also Box 1) with a particular focus on infections in tropical areas.

Section snippets

Africa

Africa is clearly the continent with the most recent scientific progress in terms of hantavirus epizootiology and epidemiology. Ten years ago, no indigenous African hantaviruses were known, while today, approximately 10 hantaviruses have been identified not only in rodents but also shrews and even bats in Africa.

Several seroepidemiological studies in African humans suggested the presence of hantaviruses in Africa much earlier (for a comprehensive review, see [100]). However, the first African

Laboratory methods

Usual laboratory findings in both HFRS and HCPS are thrombocytopenia, increased haematocrit, leukocytosis, and increased serum creatinine. Other laboratory markers depend on the preferentially targeted organ and its failure. Hantavirus isolation in cell culture is not a routine procedure for laboratory diagnosis because it is laborious, time-consuming and can only be performed by trained personnel in biosafety level 3 laboratories [95].

Considering that HFRS and HCPS are rapidly progressive

Treatment and prophylaxis

Treatment of disease is based on the clinical symptoms and occasionally includes hemodialysis, oxygenization, and/or shock therapy. There is no specific antiviral chemotherapy available. Ribavirin is the only established antiviral drug with some in vitro and in vivo-effects against hantavirus replication [81], [60]. However, its action is rather virus-nonspecific and its therapeutic use leads to side effects, such as anemia. The efficacy of ribavirin therapy given to HTNV-infected suckling mice

Conclusions and outlook on the next decade (see also Box 2)

In the next years, we expect an extended search for hantavirus occurrence and epidemiology in geographical “terrae incognitae” of all continents, including Africa and Australia. This includes the quest to identify the presence of (new) hantaviruses in (new) hosts and the clinical relevance of newly discovered hantaviruses. The finding of new hantaviruses requires the development of respective serodiagnostic tools to investigate their seroepidemiology and their clinical relevance in infected

Funding

Work from the laboratories of the authors was supported by various research grants. Writing of this review paper was not supported by special funding.

Competing interests

None declared.

Ethical approval

None.

Acknowledgement

We thank Jan ter Meulen (Seattle, WA) for encouragement and helpful suggestions, Ric Yanagihara (Honolulu, HI) for critical reading, and Christina Grübel (Berlin) for her help in manuscript editing.

References (102)

  • C. Reusken et al.

    Factors driving hantavirus emergence in Europe

    Curr Opin Virol

    (2013)
  • J.M. Rusnak et al.

    Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea

    Antivir Res

    (2009)
  • D. Safronetz et al.

    The Syrian hamster model of hantavirus pulmonary syndrome

    Antivir Res

    (2012)
  • C. Schmaljohn

    Vaccines for hantaviruses

    Vaccine

    (2009)
  • C.S. Schmaljohn et al.

    DNA vaccines for HFRS: laboratory and clinical studies

    Virus Res

    (2014)
  • J. Schubert et al.

    Evaluation of a pan-reactive hantavirus enzyme immunoassay and of a hantavirus immunoblot for the diagnosis of nephropathia epidemica

    J Clin Virol

    (2001)
  • O.S. Shin et al.

    Distinct innate immune responses in human macrophages and endothelial cells infected with shrew-borne hantaviruses

    Virology

    (2012)
  • S.K. Taori et al.

    UK hantavirus, renal failure, and pet rats

    Lancet

    (2013)
  • M.J. Vincent et al.

    Hantavirus pulmonary syndrome in Panama: identification of novel hantaviruses and their likely reservoirs

    Virology

    (2000)
  • P.T. Witkowski et al.

    Hantaviruses in Africa

    Virus Res

    (2014)
  • J. Antonen et al.

    A severe case of Puumala hantavirus infection successfully treated with bradykinin receptor antagonist icatibant

    Scand J Infect Dis

    (2013)
  • M.M. Bergoc et al.

    Successful treatment of severe hantavirus nephritis with corticosteroids: a case report and literature review

    Ther Apher Dialys

    (2013)
  • R. Brocato et al.

    DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS)

    PLoS ONE

    (2012)
  • R.L. Brocato et al.

    A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus

    J Virol

    (2014)
  • C.H. Calisher et al.

    Assessment of ecologic and biologic factors leading to hantavirus pulmonary syndrome, Colorado, U.S.A.

    Croat Med J

    (2002)
  • L.E. Chapman et al.

    Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience

    Antivir Ther

    (1999)
  • Y.K. Chu et al.

    Cross-neutralization of hantaviruses with immune sera from experimentally infected animals and from hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome patients

    J Infect Dis

    (1995)
  • J. Clement et al.

    A unifying hypothesis and a single name for a complex globally emerging infection: hantavirus disease

    Eur J Clin Microbiol Infect Dis

    (2012)
  • J. Ettinger et al.

    Multiple synchronous outbreaks of Puumala virus, Germany, 2010

    Emerg Infect Dis

    (2012)
  • M. Ferres et al.

    Prospective evaluation of household contacts of persons with hantavirus cardiopulmonary syndrome in Chile

    J Infect Dis

    (2007)
  • L.T.M. Figueiredo et al.

    Expression of a hantavirus N protein and its efficacy as antigen in immune assays

    Braz J Med Biol Res

    (2008)
  • L.T.M. Figueiredo et al.

    Evaluation of a solid-phase enzyme immunoassay based on Araraquara Hantavirus recombinant nucleoprotein

    Am J Trop Med Hyg

    (2009)
  • L.T. Figueiredo et al.

    Hantavirus pulmonary syndrome, central plateau, southeastern, and southern Brazil

    Emerg Infect Dis

    (2009)
  • C.D. Gamage et al.

    Serological evidence of Thailand virus-related hantavirus infection among suspected leptospirosis patients in Kandy, Sri Lanka

    Jpn J Infect Dis

    (2011)
  • J. Groen et al.

    A macaque model for hantavirus infection

    J Infect Dis

    (1995)
  • C.D. Hammerbeck et al.

    Hantavirus

  • J. Hardestam et al.

    Ex vivo stability of the rodent-borne Hantaan virus in comparison to that of arthropod-borne members of the Bunyaviridae family

    Appl Environ Microbiol

    (2007)
  • X. He et al.

    Changes in age distribution of hemorrhagic fever with renal syndrome: an implication of China's expanded program of immunization

    BMC Publ Health

    (2013)
  • P. Heyman et al.

    A five-year perspective on the situation of haemorrhagic fever with renal syndrome and status of the hantavirus reservoirs in Europe, 2005–2010

    EuroSurveillance

    (2011)
  • J. Hofmann et al.

    Hantavirus outbreak, Germany, 2007

    Emerg Infect Dis

    (2008)
  • J.W. Hooper et al.

    Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus

    J Virol

    (2008)
  • J.W. Huggins et al.

    Ribavirin therapy for Hantaan virus infection in suckling mice

    J Infect Dis

    (1986)
  • J.W. Huggins et al.

    Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome

    J Infect Dis

    (1991)
  • J.P. Hugot et al.

    Genetic analysis of Thailand hantavirus in Bandicota indica trapped in Thailand

    Virol J

    (2006)
  • L.J. Jameson et al.

    The continued emergence of hantaviruses: isolation of a Seoul virus implicated in human disease, United Kingdom, October 2012

    EuroSurveillance

    (2013)
  • L.J. Jameson et al.

    Pet rats as a source of hantavirus in England and Wales, 2013

    EuroSurveillance

    (2013)
  • C.B. Jonsson et al.

    A global perspective: hantavirus ecology, epidemiology and disease

    Clin Microbiol Rev

    (2010)
  • B. Klempa et al.

    Occurrence of renal and pulmonary syndrome in a region of northeast Germany where Tula hantavirus circulates

    J Clin Microbiol

    (2003)
  • B. Klempa et al.

    Hantavirus in African Wood Mouse, Guinea

    Emerg Infect Dis

    (2006)
  • B. Klempa et al.

    Hemorrhagic fever with renal syndrome caused by 2 lineages of Dobrava hantavirus, Russia

    Emerg Infect Dis

    (2008)
  • Cited by (141)

    • A fatal case of haemorrhagic fever with renal syndrome in Kursk Region, Russia, caused by a novel Puumala virus clade

      2022, Infection, Genetics and Evolution
      Citation Excerpt :

      Apparently, this is due to the fact that hantaviruses actively multiply in leukocytes, including dendritic cells, which migrate into the regional lymph nodes and spleen, where they stimulate the proliferation and differentiation of antigen-specific lymphocytes. This assumption can be indirectly confirmed by the high viral load in lymph nodes identified in the case of the Sochi infection (Kruger et al., 2015a, 2015b). Moreover, the active multiplication of Puumala virus in monocytes, macrophages/histiocytes, and dendritic cells is a prominent feature of hantaviral pathogenicity (Raftery et al., 2020).

    • Urinary Tract Infections: Virus

      2022, Encyclopedia of Infection and Immunity
    • Hantavirus Disease: A Global Update over the Last Decade

      2024, Rising Contagious Diseases: Basics, Management, and Treatments
    View all citing articles on Scopus
    View full text